Dec 21, 2017
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Dec 12, 2017
Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term
Dec 12, 2017
AbbVie Announces Phase 3 Study of VENCLEXTA(TM)/ VENCLYXTO(TM) (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint
Dec 11, 2017
People Aged 75 Years and Older Are Underrepresented in Blood Cancer Clinical Trials
Dec 11, 2017
IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition
Dec 10, 2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Dec 10, 2017
Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies
Dec 09, 2017
IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients
Dec 06, 2017
Statement by the Honourable Dominic LeBlanc and Dr. Nicholas Finn, Hematologist-Oncologist
Dec 05, 2017
Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström's Macroglobulinemia Met Primary Endpoint
Dec 05, 2017
IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint
Dec 01, 2017
B-Cell Chronic Lymphocytic Leukemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Nov 24, 2017
People Willing to Trade Treatment Efficacy for Reduced Side Effects in Cancer Therapies
Nov 21, 2017
Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients
Oct 31, 2017
US FDA APPROVES ASTRAZENECA'S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA
Oct 31, 2017
Global Immunoglobulin Market Expected to Reach $13,619 Million by 2023 - Allied Market Research
Oct 09, 2017
Hematologic Malignancies Market Size Worth $85.8 Billion by 2025: Grand View Research, Inc.
Sep 22, 2017
Nation's Experts in Hematologic Malignancies to Discuss Latest Treatment Advances and Examine Patient Cases during NCCN 12th Annual Congress
Sep 18, 2017
AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA(TM)/VENCLYXTO(TM) (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Aug 31, 2017
National Survey of 1,000 Americans Reveals Striking Lack of Knowledge of Major Cancer Killer